U.S. health authorities said Thursday that 16- and 17-year-olds should get a booster dose of Pfizer's COVID-19 vaccine once they're six months past their last shot.
The U.S. and many other nations already were urging adults to get booster shots to pump up immunity that can wane months after vaccination, calls that intensified with the discovery of the worrisome new omicron variant.
On Thursday, the Food and Drug Administration gave emergency authorization for 16- and 17-year-olds to get a third dose of the vaccine made by Pfizer and its partner BioNTech. And hours later, the Centers for Disease Control and Prevention lifted the last barrier — saying those teens should get their booster as soon as it's time.
CDC Director Rochelle Walensky told The Associated Press the boosters are important considering that protection against infection wanes over time and “we’re facing a variant that has the potential to require more immunity to be protected.”
“Vaccination and getting a booster when eligible, along with other preventive measures like masking and avoiding large crowds and poorly ventilated spaces, remain our most effective methods for fighting COVID-19,” Dr. Janet Woodcock, acting FDA commissioner, said in a statement.
The Pfizer vaccine is the only option in the U.S. for anyone younger than 18, either for initial vaccination or for use as a booster. It’s not yet clear if or when teens younger than 16 might need a third Pfizer dose.
Vaccinations for children as young as 5 just began last month, using special low-dose Pfizer shots. By this week, about 5 million 5- to 11-year-olds had gotten a first dose.
The extra-contagious delta variant is causing nearly all COVID-19 infections in the U.S., and in much of the world. It’s not yet clear how vaccines will hold up against the new and markedly different omicron mutant. But there’s strong evidence that boosters offer a jump in protection against delta-caused infections, currently the biggest threat.
Complicating the decision to extend boosters to 16- and 17-year-olds is that the Pfizer shot -- and a similar vaccine made by Moderna -- have been linked to a rare side effect. Called myocarditis, it’s a type of heart inflammation seen mostly in younger men and teen boys.
The FDA said rising COVID-19 cases in the U.S. mean the benefits of boosters greatly outweighed the potential risk from the rare side effect, especially as the coronavirus itself can cause more serious heart inflammation.
Health officials in Israel, which already gives boosters to teens, have said the side effect continues to be rare with third doses.
A U.S. study this week offered additional reassurance. Researchers from children’s hospitals around the country checked medical records and found the rare side effect usually is mild and people recover quickly. The research was published Monday in the journal Circulation.
___
Associated Press reporter Matthew Perrone contributed to this report.
Dr. Farhan Bhatti, a family physician and Michigan State lead for the Committee to Protect Health Care, joined Cheddar to discuss the newly discovered and highly transmissible omicron variant of COVID-19. Bhatti said it is too early to draw any conclusions about the new variant but there is concern that it could eventually mutate and develop a resistance to vaccines. "Time will tell, but for now, it looks like, still, the best thing that we can do to try to limit the spread of this disease is make sure everybody gets a vaccine and make sure everybody avoids large gatherings indoors and wears masks during the wintertime especially," he said.
Jill and Carlo cover the latest developments with the Omicron variant that are spooking markets once again. Twitter's @Jack is leaving, SCOTUS takes up abortion rights and the world has a brand new republic.
A CDC panel unanimously endorsed Moderna and Pfizer Covid-19 vaccine boosters for all U.S. adults. This comes after the FDA gave its own authorization for everyone 18 and older, scrapping previous eligibility factors like age and underlying conditions. Dr. Shereef Elnahal, President and CEO of University Hospital and former New Jersey Health Commissioner, joined Cheddar News to break down the development.
The Biden Administration is set to buy 10 million courses of Pfizer's Covid pill if it gains emergency use authorization from the FDA. With this purchase, the U.S. will receive more than 13 million courses of antiviral pills aimed at treating Covid and reducing severe illness and death. Pfizer's pill has been shown to reduce risk of hospitalization and death by 89 percent, proving it could be a key tool in the fight against the pandemic. Dr. Soumi Eachempati, Co-Founder, CEO & CMO of Cleared4, joined Cheddar News to discuss.
Dr. David Dodson, Infectious Disease Specialist at Carden & Dodson MD, joined Wake Up With Cheddar to break down what we know so far about the Omicron Covid-19 variant, and why you shouldn't wait for an Omicron-specific shot to get vaccinated.
Friday saw big sell offs, with the Dow Jones posting its worst day since October 2020, falling 905 points, with the Nasdaq and S&P 500 each tumbling more than two percent as well. Much of that due to investor concerns over the new Covid-19 'Omicron' variant first detected in South Africa. Craig Erlam, senior market analyst at Oanda explains what investors should expect this week.
The ocean is an important topic when it comes to the climate. It plays a vital role in shaping our environment, with rising sea levels causing a 35% increase in natural disasters around the world, affecting 1.7 billion people. Dr. Sylvia Earle has been called perhaps the greatest advocate our oceans have ever had, with Time magazine dubbing her its first 'hero of the planet' and the Library of Congress naming her a living legend. She is also the founder of Mission Blue, an organization that inspires action to explore and protect the ocean. Dr. Earle joined Cheddar Climate for more on the importance of caring for the ocean and its impact on climate change.
Scientists are racing to understand the Omicron variant of covid-19 and find out just how dangerous it really is. Omicron, dubbed a variant of concern by the WHO, was first detected in South Africa last week and has already spread to multiple countries, including the UK, Canada, Australia and more. Dr. Jonathan Javitt, CEO of Nrx and adjunct professor at Johns Hopkins School of Medicine, joined Cheddar to discuss what we know and don't know about this new variant.
The House has officially passed the $1.75 trillion social policy and climate big. This new bill is expected to bring some huge investments into working towards fighting climate change. U.S. President of We Don't Have Time, Sweta Chakraborty, joined Cheddar to discuss more.
